Vasculitis – Non-ANCA-Associated & Related Disorders Poster II
Monday, November 9, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study Sofia Barreira – Centro Hospitalar Universitário Lisboa Norte
9:00 AM – 11:00 AM ET
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool Alwin Sebastian, MD, MSc, MRCP – Southend University Hospital
9:00 AM – 11:00 AM ET
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment Andrea Rubbert-Roth, MD – Kantonspital St Gallen
9:00 AM – 11:00 AM ET
Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients Lara Sanchez-Bilbao, MD – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis Bates Gribbons, BS – McGovern Medical School
9:00 AM – 11:00 AM ET
Angiographic Progression of Disease in Large-Vessel Vasculitis Kaitlin A. Quinn, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
9:00 AM – 11:00 AM ET
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial John H. Stone, MD, MPH – Massachusetts General Hospital Rheumatology Unit, Harvard Medical School
9:00 AM – 11:00 AM ET
Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis Valentin S. Schäfer, MD, PhD – University Hospital Bonn
9:00 AM – 11:00 AM ET
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial John H. Stone, MD, MPH – Massachusetts General Hospital Rheumatology Unit, Harvard Medical School
9:00 AM – 11:00 AM ET
Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA Alwin Sebastian, MD, MSc, MRCP – Southend University Hospital
9:00 AM – 11:00 AM ET
Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis Luca Seitz, MD – Inselspital
9:00 AM – 11:00 AM ET
Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review Kubra Bugdayli, MD – Case Western Reserve University MetroHealth Medical Center
9:00 AM – 11:00 AM ET
Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis Shu Cao, MD – University of South Florida
9:00 AM – 11:00 AM ET
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis Naomi Serling-Boyd, MD – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation Alojzija Hocevar, MD – University Medical Center Ljubljana
9:00 AM – 11:00 AM ET
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value Georgina Espigol-Frigole, MD – Hospital Clínic de Barcelona
9:00 AM – 11:00 AM ET
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis Sonya Mehta, MD – Essentia Health
9:00 AM – 11:00 AM ET
Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis Eduardo Dourado, MD – Centro Hospitalar Universitário Lisboa Norte
9:00 AM – 11:00 AM ET
Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls Valentin S. Schäfer, MD, PhD – University Hospital Bonn
9:00 AM – 11:00 AM ET
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis Jiayi Zheng, MD – Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine
9:00 AM – 11:00 AM ET
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis Anne Bull Haaversen, MD – Martina Hansens Hospital
9:00 AM – 11:00 AM ET
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group Valentin S. Schäfer, MD, PhD – University Hospital Bonn
9:00 AM – 11:00 AM ET
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached Martin Aringer, MD – University Medical Center and Faculty of Medicine TU Dresden
9:00 AM – 11:00 AM ET
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events Shu Cao, MD – University of South Florida
9:00 AM – 11:00 AM ET
Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Valentin S. Schäfer, MD, PhD – University Hospital Bonn
9:00 AM – 11:00 AM ET
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis Joana Martinho, MD – Centro Hospitalar Universitário Lisboa Norte
9:00 AM – 11:00 AM ET
Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis Ana Rita Cruz-Machado, MD – Hospital de Santa Maria
9:00 AM – 11:00 AM ET
Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis Hussein Baalbaki, MD – Hopital du Sacre-Coeur de Montreal
9:00 AM – 11:00 AM ET
Fast-Track Giant Cell Arteritis Clinic Experience in the United States Mark Matza, MD, MBA – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis Joana Martinho, MD – Centro Hospitalar Universitário Lisboa Norte
